Unither welcomes Henrik Krüpper as new CEO

PRESS RELEASE 

Unither Pharmaceuticals welcomes Henrik Krüpper as new CEO

Paris (France), April 28, 2026 – Unither Pharmaceuticals (“Unither” or “the Group”), a leading European pharmaceutical contract development and manufacturing organisation (“CDMO”), is delighted to welcome Henrik Krüpper as Chief Executive Officer (“CEO”) of the Group, starting May 4. Henrik succeeds Eric Goupil, who has led the Group for more than 25 years and will continue to provide support in his new role as Chairman.

Henrik’s appointment marks the next phase in Unither’s growth journey and forms part of a planned and carefully managed succession process. The Group’s priorities, culture and long-term objectives remain focused on innovation and delivering high-quality solutions that meet clients’ manufacturing needs, particularly in Blow-Fill-Seal (“BFS”) products and liquid stick-packs.

Henrik brings over 25 years of experience across the specialty chemicals and pharmaceuticals sectors, having held senior roles at Siegfried and HCS Group. With a strong track record in strategic diversification, mergers and acquisitions and operational excellence, he is well suited to lead Unither through its next phase of growth.

Incumbent CEO Eric Goupil remains fully committed to Unither and will continue to support the Group in his new capacity as Chairman. Under Eric’s leadership, Unither has experienced sustained growth and strengthened its industrial footprint in France, the United States, Brazil and China, serving international clients worldwide. The Group has established itself as the global leader in Blow-Fill-Seal (BFS) unit-dose technology, with an annual production capacity of 5 billion doses.

Eric Goupil, outgoing CEO of Unither, said:
“After many rewarding years at the helm of Unither, the time has come for me to hand over the reins. Together, we have built a strong industrial group, recognised for its reliability.
I am particularly proud of our teams. Their commitment has enabled Unither to grow, innovate and earn the lasting trust of our clients.
From the very beginning, our ambition has been to improve and simplify patients’ lives. From BFS technology to its extension into injectables with Euroject®, we have continuously evolved our expertise to meet future market needs.
Henrik has the experience and vision required to lead this next phase. I am handing over a dynamic company, well positioned to continue its development.”

Henrik Krüpper, incoming CEO of Unither, added:
“I am delighted to be joining Unither at such an exciting point in its journey. The Group is built on a solid industrial foundation, recognised technological expertise and a strong culture of innovation. My priority will be to work alongside our teams to adequately support the Group’s growth for the benefit of our clients and, ultimately, patients.”

Biography of Henrik Krüpper

Henrik Krüpper holds an engineering degree and is of German nationality. He speaks German, English and French fluently. Prior to joining Unither Pharmaceuticals, he served since 2023 as Chief Operating Officer of the “Drug Substances” division at the Siegfried Group. He previously held executive leadership positions, notably as CEO of HCS Group.

ABOUT UNITHER PHARMACEUTICALS
Founded in Amiens in 1993, Unither Pharmaceuticals is an international pharmaceutical contract manufacturer specialising in the development and production of liquid formulations in unit-dose and multi-dose formats, including ophthalmic products, saline solutions and asthma medications using Blow-Fill-Seal (BFS) technology.

The Group employs 2,300 people and operates eight production sites in France, the United States, Brazil and China, as well as an R&D centre in France. In 2025, Unither Pharmaceuticals generated revenue of €512 million.

For more information, please visit: www.unither-pharma.com